Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort

The use, safety and effectiveness of crizotinib as part of the management of ROS1-rearranged NSCLC patients in a real-world Canadian clinical cohort was the focus of this retrospective review. Twenty-one ROS1-rearranged patients with advanced/metastatic disease receiving crizotinib between 2014–2020...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibson, Amanda J. W., Box, Adrian, Cheung, Winson Y., Dean, Michelle L., Elegbede, Anifat A., Hao, Desiree, Pabani, Aliyah, Sangha, Randeep, Bebb, Dafydd Gwyn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947433/
https://www.ncbi.nlm.nih.gov/pubmed/35323360
http://dx.doi.org/10.3390/curroncol29030160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8947433/
https://www.ncbi.nlm.nih.gov/pubmed/35323360
http://dx.doi.org/10.3390/curroncol29030160

Ejemplares similares